Αποτελέσματα Αναζήτησης
15 Ιαν 2024 · People who have interstitial lung disease along with systemic sclerosis are much more likely to die from disease complications than people who do not have lung disease. Around 80% to 90% are alive five years after being diagnosed with interstitial lung disease from systemic sclerosis.
Similarly, the prognostic value of lung biopsy in patients with SSc-associated ILD is of limited value whereas assessment of clinical severity and lung function impairment are better predictors of outcome.
The key elements of scleroderma lung disease involve 1) inflammation (potentially treatable); 2) lung scarring (not reversible but potentially preventable); and 3) blood vessel injury (treatable – see Pulmonary Hypertension).
9 Ιαν 2023 · The five-year survival rate (that is, patients who are still alive 5 years following diagnosis) among patients with diffuse cutaneous systemic sclerosis is about 84%. Five-year survival among patients with limited skin (cutaneous) systemic sclerosis is high — over 90%.
20 Ιαν 2021 · The purpose of this review is to highlight the recent advances in the evaluation and management of patients with pulmonary manifestations of SSc. We also engage in a systematic literature review to assess all the available data on the survival of patients with SSc after lung transplantation.
Pulmonary involvement in systemic sclerosis In scleroderma, the two most common types of direct pulmonary involvement are ILD and PH, which together account for 60% of SSc-related deaths [2].
2 Ιαν 2024 · The spectrum of pulmonary complications of SSc and an approach to their evaluation will be reviewed here. The clinical manifestations, diagnosis, therapy, and prognosis of SSc-associated ILD and PAH are discussed separately.
